SFX by Ex Libris Inc.

Title:	The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers
Source:	Pharmaceutical Research [0724-8741] Parr, Alan yr:2015

Basic

Full text

Full text available via SpringerLINK Contemporary 1997-Present

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Radwan, A. "Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity." Biopharmaceutics & drug disposition 33.7 (2012): 403-416.
description	2.	Zur, M. "The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation." European journal of pharmaceutical sciences 61.1 (2013): 11-7.
description	3.	Parr, A. "Re-introduction of a Novel Approach to the Use of Stable Isotopes in Pharmacokinetic Studies." The AAPS journal 14.3 (2012): 639-645.
description	4.	Visser, M. "Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240." European journal of pharmaceutics and biopharmaceutics 74.2 (2010): 233-238.
description	5.	Dahan, A. "Purely in Silico BCS Classification: Science Based Quality Standards for the World's Drugs." Molecular pharmaceutics 10.11 (2013): 4378-4390.
description	6.	Singh, A. "Oral formulation strategies to improve solubility of poorly water-soluble drugs." Expert opinion on drug delivery 8.10 (2011): 1-1378.
description	7.	Amidon, Gordon L. "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability." Pharmaceutical research 12.3 (1995): 413-420.
description	8.	Montague, Timothy H. "Additional results for ‘Sequential design approaches for bioequivalence studies with crossover designs’." Pharmaceutical Statistics 11.1 (2012): 8-13.
description	9.	Davit, Barbara M. "BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements." The AAPS Journal 18.3 (2016): 612-618.
description	10.	Mzayek, F. "Randomized clinical trial (RCT) with a crossover study design to examine the safety and pharmacokinetics of a 2100mg dose of AQ-13 and the effects of a standard fatty meal on its Bioava ilability." The American journal of tropical medicine and hygiene 81.5 (2009): 252-.
description	11.	Kim, T. "Evaluation of the Pharmacokinetics, Food Effect, Pharmacodynamics, and Tolerability of DA-1229, a Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers: First-in-Human Study." Clinical therapeutics 34.9 (2012): 1986-1998.
description	12.	Gamsiz, Ece D. "Predicting the Effect of Fed-State Intestinal Contents on Drug Dissolution." Pharmaceutical research 27.12 (2010): 2646-2656.
description	13.	Tian, W. "Effect of soybean-lecithin as an enhancer of buccal mucosa absorption of insulin." Bio-medical materials and engineering 22.1-3 (2012): 171-178.
description	14.	Saad, Richard J. "A technical review and clinical assessment of the wireless motility capsule." Gastroenterology & hepatology 7.12 (2011): 795-804.
description	15.	Srinarong, P. "Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants." European journal of pharmaceutics and biopharmaceutics 73.1 (2009): 154-161.
description	16.	van, Gerben G. "Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation." Antimicrobial agents and chemotherapy 54.5 (2010): 2042-2050.
description	17.	Van den Mooter G, G.. "Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25." European journal of pharmaceutical sciences 12.3 (2001): 261-269.
description	18.	Anthonypillai, C. "The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig." The Journal of pharmacology and experimental therapeutics 308.3 (2004): 912-920.
description	19.	Lindenberg Marc, M. "Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system." European journal of pharmaceutics and biopharmaceutics 58.2 (2004): 265-278.
description	20.	Yu, Lawrence X X. "Biopharmaceutics classification system: the scientific basis for biowaiver extensions." Pharmaceutical Research 19.7 (2002): 921-5.